Gefitinib adopts orphan kinases in leukemia

Research output: Contribution to journalReview article

Abstract

Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.

Original languageEnglish (US)
Pages (from-to)2600-2601
Number of pages2
JournalBlood
Volume106
Issue number8
DOIs
StatePublished - Oct 2005

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this